Entegrion to develop dehydrated blood products for U.S. Navy

08/7/2009 | American City Business Journals

The U.S. Navy has awarded two contracts worth $4 million to Entegrion for the development of blood-derived products. The first contract is for the development of Stasix, a powder containing dehydrated particles taken from human blood platelets that can be easily rehydrated and administered to halt a person's internal or external bleeding. The second is for the development of the firm's Resusix, a dehydrated human plasma product with decreased pathogens that is designed for infusion in patients to increase blood volume, treat blood clotting inconsistencies and stop bleeding.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC